Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.080
0.00 (0.00%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
3.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
CLDI News
- 7 days ago - Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency - GlobeNewsWire
- 15 days ago - Calidi prices 1.025M shares at $1.17 in registered direct offering - TheFly
- 15 days ago - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - GlobeNewsWire
- 24 days ago - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewsWire
- 2 months ago - Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - GlobeNewsWire